Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Depreciation & Amortization (CF) (2016 - 2019)

GT Biopharma (GTBP) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with -$6000.0 as the latest value for Q4 2019.

  • On a quarterly basis, Depreciation & Amortization (CF) changed N/A to -$6000.0 in Q4 2019 year-over-year; TTM through Sep 2020 was -$6000.0, a 160.0% decrease, with the full-year FY2019 number at $4000.0, down 42.86% from a year prior.
  • Depreciation & Amortization (CF) was -$6000.0 for Q4 2019 at GT Biopharma, down from $9000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $9000.0 in Q2 2019 to a low of -$6000.0 in Q4 2019.
  • A 5-year average of $1111.1 and a median of $1000.0 in 2015 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 0.0% in 2017; the steepest drop was 0.0% in 2017.
  • GT Biopharma's Depreciation & Amortization (CF) stood at $1000.0 in 2015, then changed by 0.0% to $1000.0 in 2016, then changed by 0.0% to $1000.0 in 2017, then changed by 0.0% to $1000.0 in 2018, then tumbled by 700.0% to -$6000.0 in 2019.
  • Per Business Quant, the three most recent readings for GTBP's Depreciation & Amortization (CF) are -$6000.0 (Q4 2019), $9000.0 (Q2 2019), and $1000.0 (Q1 2019).